financetom
Business
financetom
/
Business
/
Apple cuts jobs across its sales organization, Bloomberg News reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Apple cuts jobs across its sales organization, Bloomberg News reports
Nov 24, 2025 12:40 PM

Nov 24 (Reuters) - Apple ( AAPL ) has cut dozens of jobs

across its sales organization as it looks to streamline how it

offers products to businesses, schools and governments,

Bloomberg News reported on Monday, citing people familiar with

the matter.

The iPhone maker notified affected employees over the past

couple of weeks, Bloomberg said, including account managers

serving major businesses, schools and government agencies.

Staff who operate Apple's ( AAPL ) briefing centers for institutional

meetings and product demonstrations for prospective customers

were also affected, the report said.

Apple ( AAPL ) did not immediately respond to a Reuters request for

comment.

One of the major targets of the layoffs was a government

sales team working with agencies, including the U.S. Defense

Department and Justice Department, per the report.

The team had already been facing tough conditions after the

43-day government shutdown and cutbacks imposed by the

Department of Government Efficiency, or DOGE, Bloomberg added.

In the past few weeks, companies including Verizon,

Synopsys ( SNPS ) and IBM ( IBM ) have announced job cuts.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer
Nov 17, 2025
Jazz Pharmaceuticals Plc ( JAZZ ) shares are popping on Monday following the company’s positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). What Happened: When compared to the control group that received trastuzumab...
Jones Lang LaSalle Offers Steady Growth Outlook, UBS Says
Jones Lang LaSalle Offers Steady Growth Outlook, UBS Says
Nov 17, 2025
02:58 PM EST, 11/17/2025 (MT Newswires) -- Jones Lang LaSalle ( JLL ) is set to benefit from improving industry tailwinds amid attractive valuation after its Q3 results, UBS Securities said in a Sunday note. The report pointed to an outlook downgrade for its Real Estate Management Services segment for the next several quarters while Q3 margin expansion disappointed, similar...
Target May Tighten 2025 Outlook as Q3 Comps Stay Weak, Oppenheimer Says
Target May Tighten 2025 Outlook as Q3 Comps Stay Weak, Oppenheimer Says
Nov 17, 2025
02:46 PM EST, 11/17/2025 (MT Newswires) -- Target ( TGT ) is likely to post soft Q3 on Wednesday with comparable sales down about 2% and could narrow its fiscal 2025 earnings per share guidance toward the low end of its $7 to $9 range, Oppenheimer said Monday in a pre-results report. Oppenheimer said it added conservatism to its Q4...
Liberty Defense Up Near 14% On Contract Win for Multiple HEXWAVE Walkthrough Screening Systems From a U.S. State Capitol Complex
Liberty Defense Up Near 14% On Contract Win for Multiple HEXWAVE Walkthrough Screening Systems From a U.S. State Capitol Complex
Nov 17, 2025
03:04 PM EST, 11/17/2025 (MT Newswires) -- Liberty Defense Holdings ( LDDFF ) shares were up near 14% on Monday after it received a competitive bid award for three HEXWAVE walkthrough screening systems at a U.S. State Capitol complex in the Northeast. The company said the systems will support security screening for officials, employees, and visitors across two high-traffic buildings....
Copyright 2023-2025 - www.financetom.com All Rights Reserved